Cost-Effectiveness Analysis: Measuring the Value of Generic Drugs

When you fill a prescription for a generic drug, you’re not just saving money-you’re helping the whole system work better. But how do we know which generics actually offer the best value? That’s where cost-effectiveness analysis comes in. It’s not about which drug is cheapest on the shelf. It’s about which one delivers the most health for every dollar spent.

Why Generic Drugs Aren’t All the Same

Many people assume all generics are identical to their brand-name versions. That’s mostly true for active ingredients. But when it comes to price? Not even close. Two pills with the same chemical makeup can cost wildly different amounts just because they’re made by different companies or sold in different forms.

A 2022 study in JAMA Network Open looked at the top 1,000 generic drugs used in the U.S. and found something shocking: 45 of them were being sold at prices more than 15 times higher than other generics in the same therapeutic class. One drug, for example, cost $720 per month-while a therapeutically equivalent alternative cost just $46. That’s not a mistake. It’s a market failure.

The reason? It’s not about quality. It’s about supply, demand, and how pharmacy benefit managers (PBMs) structure contracts. PBMs often profit from the gap between what they charge insurers and what they pay pharmacies. If a higher-priced generic gives them a bigger spread, they’ll keep it on the formulary-even if a cheaper, equally effective option exists.

How Cost-Effectiveness Analysis Works

Cost-effectiveness analysis (CEA) measures how much health you get for your money. The most common metric is the incremental cost-effectiveness ratio, or ICER. It’s calculated by dividing the extra cost of one treatment by the extra health benefit it provides-usually measured in quality-adjusted life years (QALYs).

For generics, this gets tricky. A CEA comparing a brand-name drug to its generic version is straightforward: the generic costs less, and the health outcome is the same. So the ICER is zero. But what if you’re comparing two generics? Or a generic to a different drug in the same class?

Take blood pressure meds. Two generics might both lower systolic pressure by 10 mmHg. But one costs $12 a month. The other costs $180. The cheaper one isn’t just cheaper-it’s more cost-effective. And yet, many formularies still list the expensive one.

The FDA says when the first generic enters the market, prices drop an average of 39%. With six or more competitors, prices fall over 95% below the brand-name price. So timing matters. If your CEA uses last year’s prices, you’re already out of date.

The Hidden Problem: Ignoring the Future

Here’s the biggest flaw in most cost-effectiveness studies: they treat drug prices like they’re frozen in time.

A 2021 ISPOR conference review found that 94% of published CEAs didn’t account for future generic entry. That means analysts were comparing a brand-name drug to a generic… but ignoring the fact that five more generics would hit the market in 18 months. That’s like judging a car’s fuel efficiency based on 2010 gas prices and not realizing electric vehicles are now 70% cheaper to run.

Dr. John Garrison put it bluntly: “Failing to model patent expiration creates pricing anomalies that distort incentives for innovation.” If a company knows their CEA won’t consider future competition, they’ll price their drug high, assuming the analysis will lock in their premium.

The NIH now recommends that any CEA for a drug nearing patent expiry must include projected price declines. That’s not optional anymore. It’s basic math.

Therapeutic Substitution: The Hidden Savings Opportunity

You don’t always need to switch to a generic of the same drug. Sometimes, switching to a different drug in the same class saves even more.

The same JAMA study found that when patients switched from a high-cost generic to a lower-cost therapeutic alternative, savings jumped to nearly 90%. In some cases, the price difference was over 20 times.

For example:

• Generic Amlodipine (a blood pressure pill) costs $3/month
• Generic Lisinopril (a different blood pressure pill) costs $5/month
• But a high-cost generic like Telmisartan? $180/month

All three drugs do the same job. All three are FDA-approved. But only one is being priced like a luxury item.

This is therapeutic substitution-and it’s the easiest way to cut costs without hurting outcomes. Yet most health plans don’t even track it.

Why U.S. Payers Lag Behind

In Europe, over 90% of health technology assessment (HTA) agencies use formal CEA to decide which drugs to cover. In the U.S.? Only 35% of commercial insurers do, according to a 2022 AMCP survey.

Why? It’s not because they don’t care. It’s because they’re stuck in a broken system. Many use outdated pricing data. Some rely on formularies built by PBMs who benefit from higher prices. Others just don’t have the staff trained to run these analyses.

The Institute for Clinical and Economic Review (ICER) does it right. Their reports include detailed models of price erosion over time, patent cliffs, and competitor entry. But most insurers don’t have that luxury. They’re using spreadsheets from 2019.

Meanwhile, the VA and Medicare Part D have started adjusting their pricing benchmarks. The VA now uses 27% of AWP for generics, while brand-name drugs are adjusted at 64%. That’s a big deal. It means their formularies reflect real market prices-not inflated list prices.

What Needs to Change

To make cost-effectiveness analysis work for generics, three things need to happen:

1. Use real-time pricing data. Don’t rely on AWP or FSS. Use actual transaction prices from Medicaid, VA, or Medicare Part D. These reflect what’s really being paid.
2. Model future generic entry. If a patent expires in 12 months, your CEA should reflect the price drop that will follow. Assume 80%+ reduction after six competitors enter.
3. Encourage therapeutic substitution. Don’t just look at same-drug generics. Look across the whole class. The biggest savings often come from switching to a cheaper drug in the same category, not the same drug.

The U.S. spent over $250 billion on prescriptions in 2022. Generics made up 90% of prescriptions but only 17% of the cost. That’s a win. But if we’re still paying $180 for a $5 drug? We’re leaving billions on the table.

What Patients and Providers Can Do

You don’t need to be an economist to make a difference.

- Ask your pharmacist: “Is there a cheaper drug in the same class?”

- Check GoodRx or SingleCare before filling a prescription.

- If your plan denies a cheaper generic, appeal. Many times, they’ll approve it after a review.

Providers, too: when prescribing, don’t default to the brand or the first generic listed. Ask: “What’s the lowest-cost option with the same effect?”

The system isn’t broken because generics are ineffective. It’s broken because we stopped asking the right questions.

Future Trends: What’s Coming Next

Between 2020 and 2025, over 300 small-molecule drugs will lose patent protection. That’s a wave of generics about to crash into the market. If we don’t update our analysis methods now, we’ll be stuck with outdated models that miss the biggest savings opportunities.

The Inflation Reduction Act of 2022 is pushing Medicare to negotiate prices. That’s a start. But the real power lies in how we use CEA to guide those negotiations.

The NIH’s 2023 framework says it best: “Pharmaceutical pricing is endogenous to the HTA process.” In plain terms? Manufacturers set prices just below what payers are willing to pay. If we keep using old data, they’ll keep pricing high. If we model future competition accurately, we force prices down.

This isn’t about cutting corners. It’s about getting more value from every dollar spent on health care. And for generics? The savings are already there. We just need to see them.